{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:07:46Z","timestamp":1793689666021,"version":"4.5.1"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Medical and Health Science and Technology Program of Zhejiang Province","award":["2023KY1252"],"award-info":[{"award-number":["2023KY1252"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01388-y","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:22:59Z","timestamp":1775553779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Review on Photodynamic Therapy Combined with T-Cell Immunotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Mechanisms, Challenges, and Future Directions"],"prefix":"10.1007","volume":"27","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"1388_CR1","doi-asserted-by":"publisher","first-page":"1394754doi","DOI":"10.3389\/fphar.2024.1394754","volume":"15","author":"C Bian","year":"2024","unstructured":"Bian C, Zheng Z, Su J, et al. Concurrent chemoradiotherapy with S-1 versus platinum in the treatment of locoregionally advanced nasopharyngeal carcinoma: a multicenter, retrospective, propensity score-matched analysis. Front Pharmacol. 2024;15:1394754doi. https:\/\/doi.org\/10.3389\/fphar.2024.1394754.","journal-title":"Front Pharmacol"},{"key":"1388_CR2","doi-asserted-by":"publisher","unstructured":"Huang H, Yao Y, Deng X, et al. Immunotherapy for nasopharyngeal carcinoma: current status and prospects (Review). Int J Oncol. 2023;63(2). https:\/\/doi.org\/10.3892\/ijo.2023.5545.","DOI":"10.3892\/ijo.2023.5545"},{"key":"1388_CR3","doi-asserted-by":"publisher","unstructured":"Spano JP, Busson P, Atlan D et al. Nasopharyngeal carcinomas: an update. European journal of cancer (Oxford, England: 1990) 2003;39(15):2121-35.https:\/\/doi.org\/10.1016\/s0959-8049(03)00367-8","DOI":"10.1016\/s0959-8049(03)00367-8"},{"issue":"1","key":"1388_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12967-022-03446-z","volume":"20","author":"Z Xie","year":"2022","unstructured":"Xie Z, Li W, Ai J, et al. C2orf40 inhibits metastasis and regulates chemo-resistance and radio-resistance of nasopharyngeal carcinoma cells by influencing cell cycle and activating the PI3K\/AKT\/mTOR signaling pathway. J translational Med. 2022;20(1):264. https:\/\/doi.org\/10.1186\/s12967-022-03446-z.","journal-title":"J translational Med"},{"key":"1388_CR5","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.2147\/cmar.S341472","volume":"14","author":"R Jiromaru","year":"2022","unstructured":"Jiromaru R, Nakagawa T, Yasumatsu R. Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options. Cancer Manage Res. 2022;14:2681\u201389. https:\/\/doi.org\/10.2147\/cmar.S341472.","journal-title":"Cancer Manage Res"},{"key":"1388_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/dddt.S30753","volume":"7","author":"L Zhang","year":"2013","unstructured":"Zhang L, Chen QY, Liu H, et al. Emerging treatment options for nasopharyngeal carcinoma. Drug Des Devel Ther. 2013;7:37\u201352. https:\/\/doi.org\/10.2147\/dddt.S30753.","journal-title":"Drug Des Devel Ther"},{"key":"1388_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2147\/ott.S28032","volume":"5","author":"DE Spratt","year":"2012","unstructured":"Spratt DE, Lee N. Current and emerging treatment options for nasopharyngeal carcinoma. OncoTargets therapy. 2012;5:297\u2013308. https:\/\/doi.org\/10.2147\/ott.S28032.","journal-title":"OncoTargets therapy"},{"key":"1388_CR8","doi-asserted-by":"crossref","unstructured":"Soncin M, Busetti A, Fusi F et al. Irradiation of amelanotic melanoma cells with 532 nm high peak power pulsed laser radiation in the presence of the photothermal sensitizer Cu (II)-hematoporphyrin: a new approach to cell photoinactivation. Photochem Photobiol. 1999;69(6):708\u201312.","DOI":"10.1111\/j.1751-1097.1999.tb03351.x"},{"key":"1388_CR9","doi-asserted-by":"publisher","unstructured":"Ailioaie LM, Litscher G. Probiotics, Photobiomodulation, and disease management: controversies and challenges. Int J Mol Sci. 2021;22(9). https:\/\/doi.org\/10.3390\/ijms22094942.","DOI":"10.3390\/ijms22094942"},{"issue":"5","key":"1388_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1445-2197.1991.tb00230.x","volume":"61","author":"MD Daniell","year":"1991","unstructured":"Daniell MD, Hill JS. A history of photodynamic therapy. Aust N Z J Surg. 1991;61(5):340\u20138. https:\/\/doi.org\/10.1111\/j.1445-2197.1991.tb00230.x.","journal-title":"Aust N Z J Surg"},{"issue":"3","key":"1388_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3934\/biophy.2017.3.337","volume":"4","author":"MR Hamblin","year":"2017","unstructured":"Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337\u201361. https:\/\/doi.org\/10.3934\/biophy.2017.3.337.","journal-title":"AIMS Biophys"},{"issue":"5","key":"1388_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nrc1071","volume":"3","author":"DE Dolmans","year":"2003","unstructured":"Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3(5):380\u20137. https:\/\/doi.org\/10.1038\/nrc1071.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1388_CR13","doi-asserted-by":"publisher","first-page":"2002504","DOI":"10.1002\/advs.202002504","volume":"8","author":"X Deng","year":"2021","unstructured":"Deng X, Shao Z, Zhao Y. Solutions to the Drawbacks of Photothermal and Photodynamic Cancer Therapy. Adv Sci (Weinheim Baden-Wurttemberg Germany). 2021;8(3):2002504. https:\/\/doi.org\/10.1002\/advs.202002504.","journal-title":"Adv Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"1388_CR14","doi-asserted-by":"publisher","first-page":"863107doi","DOI":"10.3389\/fonc.2022.863107","volume":"12","author":"L Tan","year":"2022","unstructured":"Tan L, Shen X, He Z, et al. The Role of Photodynamic Therapy in Triggering Cell Death and Facilitating Antitumor Immunology. Front Oncol. 2022;12:863107doi. https:\/\/doi.org\/10.3389\/fonc.2022.863107.","journal-title":"Front Oncol"},{"issue":"10","key":"1388_CR15","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/2326-6066.Cir-17-0055","volume":"5","author":"JW Kleinovink","year":"2017","unstructured":"Kleinovink JW, Fransen MF, L\u00f6wik CW, et al. Photodynamic-Immune Checkpoint Therapy Eradicates Local and Distant Tumors by CD8(+) T Cells. Cancer Immunol Res. 2017;5(10):832\u201338. https:\/\/doi.org\/10.1158\/2326-6066.Cir-17-0055.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1388_CR16","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1634\/theoncologist.2017-0577","volume":"24","author":"L Chen","year":"2019","unstructured":"Chen L, Zhang Y, Lai SZ, et al. 10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma. Oncologist. 2019;24(1):e38\u201345. https:\/\/doi.org\/10.1634\/theoncologist.2017-0577.","journal-title":"Oncologist"},{"key":"1388_CR17","doi-asserted-by":"publisher","unstructured":"Juarez-Vignon Whaley JJ, Afkhami M, Onyshchenko M et al. Recurrent\/metastatic nasopharyngeal carcinoma treatment from present to future: where are we and where are we heading? current treatment options in oncology 2023;24(9):1138\u201366. https:\/\/doi.org\/10.1007\/s11864-023-01101-3","DOI":"10.1007\/s11864-023-01101-3"},{"key":"1388_CR18","doi-asserted-by":"publisher","first-page":"693199","DOI":"10.3389\/fonc.2021.693199","volume":"11","author":"S Chen","year":"2021","unstructured":"Chen S, Yang D, Liao X, et al. Failure Patterns of Recurrence and Metastasis After Intensity-Modulated Radiotherapy in Patients With Nasopharyngeal Carcinoma: Results of a Multicentric Clinical Study. Front Oncol. 2021;11:693199. https:\/\/doi.org\/10.3389\/fonc.2021.693199.","journal-title":"Front Oncol"},{"issue":"1","key":"1388_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s0360-3016(98)00524-0","volume":"44","author":"AW Lee","year":"1999","unstructured":"Lee AW, Foo W, Law SC, et al. Recurrent nasopharyngeal carcinoma: the puzzles of long latency. Int J Radiat Oncol Biol Phys. 1999;44(1):149\u201356. https:\/\/doi.org\/10.1016\/s0360-3016(98)00524-0.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1388_CR20","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.3747\/co.20.1456","volume":"20","author":"T Xu","year":"2013","unstructured":"Xu T, Tang J, Gu M, et al. Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge. Curr Oncol (Toronto Ont). 2013;20(5):e406\u201319. https:\/\/doi.org\/10.3747\/co.20.1456.","journal-title":"Curr Oncol (Toronto Ont)"},{"issue":"5","key":"1388_CR21","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cam4.2838","volume":"9","author":"C Chen","year":"2020","unstructured":"Chen C, Zhou Y, Zhang X, et al. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. Cancer Med. 2020;9(5):1721\u201332. https:\/\/doi.org\/10.1002\/cam4.2838.","journal-title":"Cancer Med"},{"issue":"10054","key":"1388_CR22","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/s0140-6736(16)31388-5","volume":"388","author":"L Zhang","year":"2016","unstructured":"Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet (London England). 2016;388(10054):1883\u201392. https:\/\/doi.org\/10.1016\/s0140-6736(16)31388-5.","journal-title":"Lancet (London England)"},{"issue":"29","key":"1388_CR23","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1200\/jco.21.00396","volume":"39","author":"S Hong","year":"2021","unstructured":"Hong S, Zhang Y, Yu G, et al. Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study. J Clin oncology: official J Am Soc Clin Oncol. 2021;39(29):3273\u201382. https:\/\/doi.org\/10.1200\/jco.21.00396.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"1388_CR24","doi-asserted-by":"publisher","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9). https:\/\/doi.org\/10.3390\/ijms21093233.","DOI":"10.3390\/ijms21093233"},{"issue":"18","key":"1388_CR25","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1016\/j.ejca.2012.06.016","volume":"48","author":"YJ Hua","year":"2012","unstructured":"Hua YJ, Han F, Lu LX, et al. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy. Eur J cancer (Oxford England: 1990). 2012;48(18):3422\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2012.06.016.","journal-title":"Eur J cancer (Oxford England: 1990)"},{"issue":"4","key":"1388_CR26","doi-asserted-by":"publisher","first-page":"e0125351","DOI":"10.1371\/journal.pone.0125351","volume":"10","author":"W Xiao","year":"2015","unstructured":"Xiao W, Liu S, Tian Y, et al. Prognostic significance of tumor volume in locally recurrent nasopharyngeal carcinoma treated with salvage intensity-modulated radiotherapy. PLoS ONE. 2015;10(4):e0125351. https:\/\/doi.org\/10.1371\/journal.pone.0125351.","journal-title":"PLoS ONE"},{"key":"1388_CR27","doi-asserted-by":"publisher","unstructured":"Wang R, Kang M. Guidelines for radiotherapy of nasopharyngeal carcinoma. 2021;5(3):122\u201359.https:\/\/doi.org\/10.1002\/pro6.1123","DOI":"10.1002\/pro6.1123"},{"issue":"9476","key":"1388_CR28","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/s0140-6736(05)66698-6","volume":"365","author":"WI Wei","year":"2005","unstructured":"Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet (London England). 2005;365(9476):2041\u201354. https:\/\/doi.org\/10.1016\/s0140-6736(05)66698-6.","journal-title":"Lancet (London England)"},{"issue":"1","key":"1388_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12272-020-01214-5","volume":"43","author":"J Kim","year":"2020","unstructured":"Kim J, Jo YU, Na K. Photodynamic therapy with smart nanomedicine. Arch Pharm Res. 2020;43(1):22\u201331. https:\/\/doi.org\/10.1007\/s12272-020-01214-5.","journal-title":"Arch Pharm Res"},{"issue":"3","key":"1388_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12094-008-0172-2","volume":"10","author":"A Juarranz","year":"2008","unstructured":"Juarranz A, Ja\u00e9n P, Sanz-Rodr\u00edguez F, et al. Photodynamic therapy of cancer. Basic principles and applications. Clinical & translational oncology: official publication of the Federation of. Span Oncol Soc Natl Cancer Inst Mexico. 2008;10(3):148\u201354. https:\/\/doi.org\/10.1007\/s12094-008-0172-2.","journal-title":"Span Oncol Soc Natl Cancer Inst Mexico"},{"issue":"5","key":"1388_CR31","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1021\/cr900300p","volume":"110","author":"JP Celli","year":"2010","unstructured":"Celli JP, Spring BQ, Rizvi I, et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev. 2010;110(5):2795\u2013838. https:\/\/doi.org\/10.1021\/cr900300p.","journal-title":"Chem Rev"},{"issue":"3","key":"1388_CR32","doi-asserted-by":"publisher","first-page":"e1122","DOI":"10.1038\/cddis.2014.77","volume":"5","author":"P Acedo","year":"2014","unstructured":"Acedo P, Stockert JC, Ca\u00f1ete M, et al. Two combined photosensitizers: a goal for more effective photodynamic therapy of cancer. Cell Death Dis. 2014;5(3):e1122. https:\/\/doi.org\/10.1038\/cddis.2014.77.","journal-title":"Cell Death Dis"},{"issue":"4","key":"1388_CR33","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/sj.bjp.0705295","volume":"139","author":"YP An","year":"2003","unstructured":"An YP, Xiao R, Cui H, et al. Selective activation by photodynamic action of cholecystokinin receptor in the freshly isolated rat pancreatic acini. Br J Pharmacol. 2003;139(4):872\u201380. https:\/\/doi.org\/10.1038\/sj.bjp.0705295.","journal-title":"Br J Pharmacol"},{"issue":"34","key":"1388_CR34","doi-asserted-by":"publisher","first-page":"9947","DOI":"10.1002\/anie.201604130","volume":"55","author":"W Lv","year":"2016","unstructured":"Lv W, Zhang Z, Zhang KY, et al. A Mitochondria-Targeted Photosensitizer Showing Improved Photodynamic Therapy Effects Under Hypoxia. Angewandte Chemie (International ed English). 2016;55(34):9947\u201351. https:\/\/doi.org\/10.1002\/anie.201604130.","journal-title":"Angewandte Chemie (International ed English)"},{"issue":"27","key":"1388_CR35","doi-asserted-by":"publisher","first-page":"e1901893","DOI":"10.1002\/adma.201901893","volume":"31","author":"D Wang","year":"2019","unstructured":"Wang D, Wu H, Lim WQ, et al. A Mesoporous Nanoenzyme Derived from Metal-Organic Frameworks with Endogenous Oxygen Generation to Alleviate Tumor Hypoxia for Significantly Enhanced Photodynamic Therapy. Advanced materials (Deerfield Beach. Fla). 2019;31(27):e1901893. https:\/\/doi.org\/10.1002\/adma.201901893.","journal-title":"Fla)"},{"issue":"40","key":"1388_CR36","doi-asserted-by":"publisher","first-page":"14213","DOI":"10.1002\/anie.201909020","volume":"58","author":"L Zhang","year":"2019","unstructured":"Zhang L, Wang S, Zhou Y, et al. Covalent Organic Frameworks as Favorable Constructs for Photodynamic Therapy. Angewandte Chemie (International ed English). 2019;58(40):14213\u201318. https:\/\/doi.org\/10.1002\/anie.201909020.","journal-title":"Angewandte Chemie (International ed English)"},{"issue":"2","key":"1388_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.bbrc.2009.05.035","volume":"385","author":"AG Pakhomov","year":"2009","unstructured":"Pakhomov AG, Bowman AM, Ibey BL, et al. Lipid nanopores can form a stable, ion channel-like conduction pathway in cell membrane. Biochem Biophys Res Commun. 2009;385(2):181\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2009.05.035.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"1388_CR38","first-page":"372","volume":"45","author":"J Labanauskiene","year":"2009","unstructured":"Labanauskiene J, Satkauskas S, Kirveliene V, et al. Enhancement of photodynamic tumor therapy effectiveness by electroporation in vitro. Med (Kaunas Lithuania). 2009;45(5):372\u20137.","journal-title":"Med (Kaunas Lithuania)"},{"issue":"2","key":"1388_CR39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.pdpdt.2012.01.004","volume":"9","author":"S Abbas","year":"2012","unstructured":"Abbas S, Jerjes W, Upile T, et al. The palliative role of PDT in recurrent advanced nasopharyngeal carcinoma: case series. Photodiagn Photodyn Ther. 2012;9(2):142\u20137. https:\/\/doi.org\/10.1016\/j.pdpdt.2012.01.004.","journal-title":"Photodiagn Photodyn Ther"},{"issue":"9","key":"1388_CR40","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1001\/archotol.1995.01890090039008","volume":"121","author":"LA Lofgren","year":"1995","unstructured":"Lofgren LA, Hallgren S, Nilsson E, et al. Photodynamic therapy for recurrent nasopharyngeal cancer. Archives otolaryngology\u2013head neck Surg. 1995;121(9):997\u20131002. https:\/\/doi.org\/10.1001\/archotol.1995.01890090039008.","journal-title":"Archives otolaryngology\u2013head neck Surg"},{"issue":"3","key":"1388_CR41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/bf00615121","volume":"253","author":"MC Tong","year":"1996","unstructured":"Tong MC, van Hasselt CA, Woo JK. Preliminary results of photodynamic therapy for recurrent nasopharyngeal carcinoma. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology -. Head Neck Surg. 1996;253(3):189\u201392. https:\/\/doi.org\/10.1007\/bf00615121.","journal-title":"Head Neck Surg"},{"issue":"2","key":"1388_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pdpdt.2014.01.004","volume":"11","author":"G Succo","year":"2014","unstructured":"Succo G, Rosso S, Fadda GL, et al. Salvage photodynamic therapy for recurrent nasopharyngeal carcinoma. Photodiagn Photodyn Ther. 2014;11(2):63\u201370. https:\/\/doi.org\/10.1016\/j.pdpdt.2014.01.004.","journal-title":"Photodiagn Photodyn Ther"},{"issue":"4","key":"1388_CR43","doi-asserted-by":"publisher","first-page":"041107","DOI":"10.1117\/1.2338009","volume":"11","author":"RL van Veen","year":"2006","unstructured":"van Veen RL, Nyst H, Rai Indrasari S, et al. In vivo fluence rate measurements during Foscan-mediated photodynamic therapy of persistent and recurrent nasopharyngeal carcinomas using a dedicated light applicator. J Biomed Opt. 2006;11(4):041107. https:\/\/doi.org\/10.1117\/1.2338009.","journal-title":"J Biomed Opt"},{"key":"1388_CR44","doi-asserted-by":"publisher","unstructured":"Want MY, Bashir Z, Najar RA. T Cell based immunotherapy for cancer: approaches and strategies. Vaccines. 2023;11(4). https:\/\/doi.org\/10.3390\/vaccines11040835.","DOI":"10.3390\/vaccines11040835"},{"issue":"4","key":"1388_CR45","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41419-024-06616-7","volume":"15","author":"S Yang","year":"2024","unstructured":"Yang S, Wang Y, Jia J, et al. Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy. Cell Death Dis. 2024;15(4):238. https:\/\/doi.org\/10.1038\/s41419-024-06616-7.","journal-title":"Cell Death Dis"},{"issue":"7","key":"1388_CR46","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","volume":"43","author":"J Zhang","year":"2022","unstructured":"Zhang J, Huang D, Saw PE, et al. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol. 2022;43(7):523\u201345. https:\/\/doi.org\/10.1016\/j.it.2022.04.010.","journal-title":"Trends Immunol"},{"issue":"7637","key":"1388_CR47","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330. https:\/\/doi.org\/10.1038\/nature21349.","journal-title":"Nature"},{"key":"1388_CR48","doi-asserted-by":"publisher","first-page":"663201doi","DOI":"10.3389\/fimmu.2021.663201","volume":"12","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Z, Ren Z, et al. Reactions Related to CAR-T Cell Therapy. Front Immunol. 2021;12:663201doi. https:\/\/doi.org\/10.3389\/fimmu.2021.663201.","journal-title":"Front Immunol"},{"issue":"1","key":"1388_CR49","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","volume":"10","author":"Z Wang","year":"2017","unstructured":"Wang Z, Wu Z, Liu Y, et al. New development in CAR-T cell therapy. J Hematol Oncol. 2017;10(1):53. https:\/\/doi.org\/10.1186\/s13045-017-0423-1.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1388_CR50","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/cr.2016.154","volume":"27","author":"LA Johnson","year":"2017","unstructured":"Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 2017;27(1):38\u201358. https:\/\/doi.org\/10.1038\/cr.2016.154.","journal-title":"Cell Res"},{"key":"1388_CR51","doi-asserted-by":"publisher","unstructured":"Zhao Y, Deng J, Rao S, et al. Tumor Infiltrating Lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers. 2022;14(17). https:\/\/doi.org\/10.3390\/cancers14174160.","DOI":"10.3390\/cancers14174160"},{"issue":"1","key":"1388_CR52","doi-asserted-by":"publisher","first-page":"3801doi","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801doi. https:\/\/doi.org\/10.1038\/s41467-020-17670-y.","journal-title":"Nat Commun"},{"issue":"1","key":"1388_CR53","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman M, Jiao YJ, Chen JH, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136. https:\/\/doi.org\/10.1038\/s41467-017-01062-w.","journal-title":"Nat Commun"},{"issue":"1","key":"1388_CR54","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","volume":"29","author":"MH Pollack","year":"2018","unstructured":"Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Annals oncology: official J Eur Soc Med Oncol. 2018;29(1):250\u201355. https:\/\/doi.org\/10.1093\/annonc\/mdx642.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"40","key":"1388_CR55","doi-asserted-by":"publisher","first-page":"67782","DOI":"10.18632\/oncotarget.18847","volume":"8","author":"R Costa","year":"2017","unstructured":"Costa R, Costa RB, Talamantes SM, et al. Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. Oncotarget. 2017;8(40):67782\u201389. https:\/\/doi.org\/10.18632\/oncotarget.18847.","journal-title":"Oncotarget"},{"issue":"1","key":"1388_CR56","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12885-018-4295-8","volume":"18","author":"T Finazzi","year":"2018","unstructured":"Finazzi T, Rordorf T, Ikenberg K, et al. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. BMC Cancer. 2018;18(1):395. https:\/\/doi.org\/10.1186\/s12885-018-4295-8.","journal-title":"BMC Cancer"},{"issue":"10","key":"1388_CR57","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.1007\/s00415-024-12660-2","volume":"271","author":"S Pichon","year":"2024","unstructured":"Pichon S, Aigrain P, Lacombe C, et al. Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients. J Neurol. 2024;271(10):6514\u201325. https:\/\/doi.org\/10.1007\/s00415-024-12660-2.","journal-title":"J Neurol"},{"issue":"9","key":"1388_CR58","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","volume":"27","author":"HQ Mai","year":"2021","unstructured":"Mai HQ, Chen QY, Chen D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021;27(9):1536\u201343. https:\/\/doi.org\/10.1038\/s41591-021-01444-0.","journal-title":"Nat Med"},{"issue":"36","key":"1388_CR59","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/jco.2017.73.3675","volume":"35","author":"C Hsu","year":"2017","unstructured":"Hsu C, Lee SH, Ejadi S, et al. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. J Clin oncology: official J Am Soc Clin Oncol. 2017;35(36):4050\u201356. https:\/\/doi.org\/10.1200\/jco.2017.73.3675.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"10","key":"1388_CR60","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/s1470-2045(18)30495-9","volume":"19","author":"W Fang","year":"2018","unstructured":"Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19(10):1338\u201350. https:\/\/doi.org\/10.1016\/s1470-2045(18)30495-9.","journal-title":"Lancet Oncol"},{"issue":"19","key":"1388_CR61","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1158\/1078-0432.Ccr-22-1238","volume":"28","author":"HA Jung","year":"2022","unstructured":"Jung HA, Park KU, Cho S, et al. A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11). Clin cancer research: official J Am Association Cancer Res. 2022;28(19):4240\u201347. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-1238.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"11","key":"1388_CR62","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1080\/14712598.2019.1650910","volume":"19","author":"JC Chow","year":"2019","unstructured":"Chow JC, Ngan RK, Cheung KM, et al. Immunotherapeutic approaches in nasopharyngeal carcinoma. Expert Opin Biol Ther. 2019;19(11):1165\u201372. https:\/\/doi.org\/10.1080\/14712598.2019.1650910.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1388_CR63","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1038\/s41467-023-38407-7","volume":"14","author":"DW Lim","year":"2023","unstructured":"Lim DW, Kao HF, Suteja L, et al. Clinical efficacy and biomarker analysis of dual PD-1\/CTLA-4 blockade in recurrent\/metastatic EBV-associated nasopharyngeal carcinoma. Nat Commun. 2023;14(1):2781. https:\/\/doi.org\/10.1038\/s41467-023-38407-7.","journal-title":"Nat Commun"},{"issue":"1","key":"1388_CR64","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41698-024-00601-1","volume":"8","author":"X Liu","year":"2024","unstructured":"Liu X, Shen H, Zhang L, et al. Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma. NPJ precision Oncol. 2024;8(1):101. https:\/\/doi.org\/10.1038\/s41698-024-00601-1.","journal-title":"NPJ precision Oncol"},{"issue":"3","key":"1388_CR65","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.beha.2008.06.002","volume":"21","author":"CM Bollard","year":"2008","unstructured":"Bollard CM, Cooper LJ, Heslop HE. Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol. 2008;21(3):405\u201320. https:\/\/doi.org\/10.1016\/j.beha.2008.06.002.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"1388_CR66","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/mt.2013.242","volume":"22","author":"WK Chia","year":"2014","unstructured":"Chia WK, Teo M, Wang WW, et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma. Mol therapy: J Am Soc Gene Therapy. 2014;22(1):132\u20139. https:\/\/doi.org\/10.1038\/mt.2013.242.","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"issue":"14","key":"1388_CR67","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1002\/cncr.30541","volume":"123","author":"J Huang","year":"2017","unstructured":"Huang J, Fogg M, Wirth LJ, et al. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer. 2017;123(14):2642\u201350. https:\/\/doi.org\/10.1002\/cncr.30541.","journal-title":"Cancer"},{"issue":"10","key":"1388_CR68","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jcyt.2023.06.004","volume":"25","author":"Q Huo","year":"2023","unstructured":"Huo Q, Lv J, Zhang J, et al. c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma. Cytotherapy. 2023;25(10):1037\u201347. https:\/\/doi.org\/10.1016\/j.jcyt.2023.06.004.","journal-title":"Cytotherapy"},{"issue":"5","key":"1388_CR69","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1039\/c0pp00308e","volume":"10","author":"M Firczuk","year":"2011","unstructured":"Firczuk M, Nowis D, Go\u0142\u0105b J. PDT-induced inflammatory and host responses. Photochemical & photobiological sciences: Official journal of the European Photochemistry Association and the European Society. Photobiology. 2011;10(5):653\u201363. https:\/\/doi.org\/10.1039\/c0pp00308e.","journal-title":"Photobiology"},{"issue":"2","key":"1388_CR70","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1006\/clim.1999.4695","volume":"91","author":"H Jiang","year":"1999","unstructured":"Jiang H, Granville DJ, McManus BM, et al. Selective depletion of a thymocyte subset in vitro with an immunomodulatory photosensitizer. Clinical immunology (Orlando. Fla). 1999;91(2):178\u201387. https:\/\/doi.org\/10.1006\/clim.1999.4695.","journal-title":"Fla)"},{"key":"1388_CR71","doi-asserted-by":"publisher","first-page":"1514009doi","DOI":"10.3389\/fonc.2025.1514009","volume":"15","author":"Y Li","year":"2025","unstructured":"Li Y, Luo Y, Ran Y, et al. Biomarkers of inflammation and colorectal cancer risk. Front Oncol. 2025;15:1514009doi. https:\/\/doi.org\/10.3389\/fonc.2025.1514009.","journal-title":"Front Oncol"},{"issue":"4","key":"1388_CR72","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.3892\/ol.2018.9322","volume":"16","author":"F Zhang","year":"2018","unstructured":"Zhang F, Zhu Y, Fan G, et al. Photodynamic therapy reduces the inhibitory effect of osteosarcoma cells on dendritic cells by upregulating HSP70. Oncol Lett. 2018;16(4):5034\u201340. https:\/\/doi.org\/10.3892\/ol.2018.9322.","journal-title":"Oncol Lett"},{"issue":"1","key":"1388_CR73","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12672-024-01186-8","volume":"15","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Ni Q, Zhang W, et al. Progress in reeducating tumor-associated macrophages in tumor microenvironment. Discover Oncol. 2024;15(1):312. https:\/\/doi.org\/10.1007\/s12672-024-01186-8.","journal-title":"Discover Oncol"},{"issue":"3","key":"1388_CR74","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nri1785","volume":"6","author":"C Nathan","year":"2006","unstructured":"Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006;6(3):173\u201382. https:\/\/doi.org\/10.1038\/nri1785.","journal-title":"Nat Rev Immunol"},{"issue":"21","key":"1388_CR75","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1158\/0008-5472.Can-07-1778","volume":"67","author":"PC Kousis","year":"2007","unstructured":"Kousis PC, Henderson BW, Maier PG, et al. Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res. 2007;67(21):10501\u201310. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-1778.","journal-title":"Cancer Res"},{"issue":"13","key":"1388_CR76","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1158\/1078-0432.Ccr-04-0367","volume":"10","author":"A Jalili","year":"2004","unstructured":"Jalili A, Makowski M, Switaj T, et al. Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin cancer research: official J Am Association Cancer Res. 2004;10(13):4498\u2013508. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-0367.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"8","key":"1388_CR77","first-page":"1941","volume":"59","author":"M Korbelik","year":"1999","unstructured":"Korbelik M, Dougherty GJ. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res. 1999;59(8):1941\u20136.","journal-title":"Cancer Res"},{"issue":"1","key":"1388_CR78","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0304-3835(98)00349-8","volume":"137","author":"M Korbelik","year":"1999","unstructured":"Korbelik M, Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett. 1999;137(1):91\u20138. https:\/\/doi.org\/10.1016\/s0304-3835(98)00349-8.","journal-title":"Cancer Lett"},{"issue":"9","key":"1388_CR79","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1039\/c4pp00186a","volume":"13","author":"E Reginato","year":"2014","unstructured":"Reginato E, Lindenmann J, Langner C, et al. Photodynamic therapy downregulates the function of regulatory T cells in patients with esophageal squamous cell carcinoma. Photochemical photobiological sciences: Official J Eur Photochem Association Eur Soc Photobiology. 2014;13(9):1281\u20139. https:\/\/doi.org\/10.1039\/c4pp00186a.","journal-title":"Photochemical photobiological sciences: Official J Eur Photochem Association Eur Soc Photobiology"},{"key":"1388_CR80","doi-asserted-by":"crossref","unstructured":"Chen X, Song M, Zhang B et al. Reactive oxygen species regulate T cell immune response in the tumor microenvironment. Oxidative Med Cell Longev 2016;2016:158096710.1155\/2016\/1580967","DOI":"10.1155\/2016\/1580967"},{"issue":"5","key":"1388_CR81","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1084\/jem.20041684","volume":"201","author":"P Yu","year":"2005","unstructured":"Yu P, Lee Y, Liu W, et al. Intratumor depletion of CD4\u2009+\u2009cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med. 2005;201(5):779\u201391. https:\/\/doi.org\/10.1084\/jem.20041684.","journal-title":"J Exp Med"},{"issue":"8","key":"1388_CR82","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1038\/bjc.2013.580","volume":"109","author":"E Reginato","year":"2013","unstructured":"Reginato E, Mroz P, Chung H, et al. Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen. Br J Cancer. 2013;109(8):2167\u201374. https:\/\/doi.org\/10.1038\/bjc.2013.580.","journal-title":"Br J Cancer"},{"issue":"18","key":"1388_CR83","first-page":"3904","volume":"57","author":"SO Gollnick","year":"1997","unstructured":"Gollnick SO, Liu X, Owczarczak B, et al. Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res. 1997;57(18):3904\u20139.","journal-title":"Cancer Res"},{"issue":"12","key":"1388_CR84","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/sj.bjc.6603792","volume":"96","author":"E Kabingu","year":"2007","unstructured":"Kabingu E, Vaughan L, Owczarczak B, et al. CD8\u2009+\u2009T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4\u2009+\u2009T cells and dependent on natural killer cells. Br J Cancer. 2007;96(12):1839\u201348. https:\/\/doi.org\/10.1038\/sj.bjc.6603792.","journal-title":"Br J Cancer"},{"issue":"12","key":"1388_CR85","doi-asserted-by":"publisher","first-page":"e15194","DOI":"10.1371\/journal.pone.0015194","volume":"5","author":"P Mroz","year":"2010","unstructured":"Mroz P, Szokalska A, Wu MX, et al. Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLoS ONE. 2010;5(12):e15194. https:\/\/doi.org\/10.1371\/journal.pone.0015194.","journal-title":"PLoS ONE"},{"issue":"3","key":"1388_CR86","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00262-014-1633-9","volume":"64","author":"M Shams","year":"2015","unstructured":"Shams M, Owczarczak B, Manderscheid-Kern P, et al. Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease. Cancer Immunol immunotherapy: CII. 2015;64(3):287\u201397. https:\/\/doi.org\/10.1007\/s00262-014-1633-9.","journal-title":"Cancer Immunol immunotherapy: CII"},{"issue":"6","key":"1388_CR87","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1158\/1078-0432.Ccr-14-1979","volume":"21","author":"YH Lee","year":"2015","unstructured":"Lee YH, Bae HC, Noh KH, et al. Gain of HIF-1\u03b1 under normoxia in cancer mediates immune adaptation through the AKT\/ERK and VEGFA axes. Clin cancer research: official J Am Association Cancer Res. 2015;21(6):1438\u201346. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-1979.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"12","key":"1388_CR88","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","volume":"101","author":"JE Ohm","year":"2003","unstructured":"Ohm JE, Gabrilovich DI, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003;101(12):4878\u201386. https:\/\/doi.org\/10.1182\/blood-2002-07-1956.","journal-title":"Blood"},{"issue":"2","key":"1388_CR89","doi-asserted-by":"publisher","first-page":"e89646","DOI":"10.1371\/journal.pone.0089646","volume":"9","author":"AA Akhiani","year":"2014","unstructured":"Akhiani AA, Werlenius O, Aurelius J, et al. Role of the ERK pathway for oxidant-induced parthanatos in human lymphocytes. PLoS ONE. 2014;9(2):e89646. https:\/\/doi.org\/10.1371\/journal.pone.0089646.","journal-title":"PLoS ONE"},{"issue":"6","key":"1388_CR90","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/eji.1830260620","volume":"26","author":"K Kono","year":"1996","unstructured":"Kono K, Salazar-Onfray F, Petersson M, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol. 1996;26(6):1308\u201313. https:\/\/doi.org\/10.1002\/eji.1830260620.","journal-title":"Eur J Immunol"},{"issue":"11","key":"1388_CR91","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1002\/j.1460-2075.1993.tb06120.x","volume":"12","author":"H Ohno","year":"1993","unstructured":"Ohno H, Aoe T, Taki S, et al. Developmental and functional impairment of T cells in mice lacking CD3 zeta chains. EMBO J. 1993;12(11):4357\u201366. https:\/\/doi.org\/10.1002\/j.1460-2075.1993.tb06120.x.","journal-title":"EMBO J"},{"issue":"18","key":"1388_CR92","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.7150\/jca.54699","volume":"12","author":"R Huang","year":"2021","unstructured":"Huang R, Chen H, Liang J, et al. Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy. J Cancer. 2021;12(18):5543\u201361. https:\/\/doi.org\/10.7150\/jca.54699.","journal-title":"J Cancer"},{"issue":"6","key":"1388_CR93","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/php.13173","volume":"95","author":"S Nath","year":"2019","unstructured":"Nath S, Obaid G, Hasan T. The Course of Immune Stimulation by Photodynamic Therapy: Bridging Fundamentals of Photochemically Induced Immunogenic Cell Death to the Enrichment of T-Cell Repertoire. Photochem Photobiol. 2019;95(6):1288\u2013305. https:\/\/doi.org\/10.1111\/php.13173.","journal-title":"Photochem Photobiol"},{"issue":"1","key":"1388_CR94","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01928-2","volume":"23","author":"H Liu","year":"2024","unstructured":"Liu H, Tang L, Li Y, et al. Nasopharyngeal carcinoma: current views on the tumor microenvironment\u2019s impact on drug resistance and clinical outcomes. Mol Cancer. 2024;23(1):20. https:\/\/doi.org\/10.1186\/s12943-023-01928-2.","journal-title":"Mol Cancer"},{"key":"1388_CR95","doi-asserted-by":"publisher","unstructured":"Yu J, Pham TT, Wandrey N, et al. Multimodality Management of EBV-Associated Nasopharyngeal Carcinoma. Cancers. 2021;13(23). https:\/\/doi.org\/10.3390\/cancers13236078.","DOI":"10.3390\/cancers13236078"},{"issue":"11","key":"1388_CR96","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41422-020-0374-x","volume":"30","author":"YP Chen","year":"2020","unstructured":"Chen YP, Yin JH, Li WF, et al. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res. 2020;30(11):1024\u201342. https:\/\/doi.org\/10.1038\/s41422-020-0374-x.","journal-title":"Cell Res"},{"key":"1388_CR97","doi-asserted-by":"publisher","first-page":"744889","DOI":"10.3389\/fonc.2021.744889","volume":"11","author":"L Gong","year":"2021","unstructured":"Gong L, Kwong DL, Dai W, et al. The Stromal and Immune Landscape of Nasopharyngeal Carcinoma and Its Implications for Precision Medicine Targeting the Tumor Microenvironment. Front Oncol. 2021;11:744889. https:\/\/doi.org\/10.3389\/fonc.2021.744889.","journal-title":"Front Oncol"},{"key":"1388_CR98","doi-asserted-by":"publisher","first-page":"840467doi","DOI":"10.3389\/fonc.2022.840467","volume":"12","author":"ZY Su","year":"2022","unstructured":"Su ZY, Siak PY, Leong CO, et al. Nasopharyngeal Carcinoma and Its Microenvironment: Past, Current, and Future Perspectives. Front Oncol. 2022;12:840467doi. https:\/\/doi.org\/10.3389\/fonc.2022.840467.","journal-title":"Front Oncol"},{"key":"1388_CR99","doi-asserted-by":"publisher","unstructured":"Li S, Dai W, Kam NW, et al. The Role of Natural Killer Cells in the Tumor Immune Microenvironment of EBV-Associated Nasopharyngeal Carcinoma. Cancers. 2024;16(7). https:\/\/doi.org\/10.3390\/cancers16071312.","DOI":"10.3390\/cancers16071312"},{"issue":"12","key":"1388_CR100","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41565-021-00982-5","volume":"16","author":"NT Nguyen","year":"2021","unstructured":"Nguyen NT, Huang K, Zeng H, et al. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nat Nanotechnol. 2021;16(12):1424\u201334. https:\/\/doi.org\/10.1038\/s41565-021-00982-5.","journal-title":"Nat Nanotechnol"},{"issue":"3","key":"1388_CR101","first-page":"175","volume":"8","author":"D VF","year":"1996","unstructured":"VF D, Vasiliu V, Laky D, et al. Regression of Rat Carcinosarcoma by Perfusion of Tumour Infiltrating Lymphocytes in Conjunction with Haematoporphyrin Derivative and HeNe. Laser Irradiation. 1996;8(3):175\u201384.","journal-title":"Laser Irradiation"},{"issue":"1","key":"1388_CR102","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1021\/acs.molpharmaceut.8b00997","volume":"16","author":"R Bao","year":"2019","unstructured":"Bao R, Wang Y, Lai J, et al. Enhancing Anti-PD-1\/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature. Mol Pharm. 2019;16(1):339\u201348. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00997.","journal-title":"Mol Pharm"},{"issue":"6","key":"1388_CR103","doi-asserted-by":"publisher","first-page":"779","DOI":"10.21037\/tau.2019.07.10","volume":"8","author":"G Bou Kheir","year":"2019","unstructured":"Bou Kheir G, Aoun F, Roumeguere T. CD47 targeted near-infrared photo-immunotherapy: a promising tool combining monoclonal antibodies and photodynamics for treating human bladder cancer. Translational Androl Urol. 2019;8(6):779\u201380. https:\/\/doi.org\/10.21037\/tau.2019.07.10.","journal-title":"Translational Androl Urol"},{"issue":"4","key":"1388_CR104","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1158\/1535-7163.Mct-23-0733","volume":"24","author":"R McMorrow","year":"2025","unstructured":"McMorrow R, de Bruijn HS, Farina S, et al. Combination of Bremachlorin PDT and Immune Checkpoint Inhibitor Anti-PD-1 Shows Response in Murine Immunological T-cell-High and T-cell-Low PDAC Models. Mol Cancer Ther. 2025;24(4):605\u201317. https:\/\/doi.org\/10.1158\/1535-7163.Mct-23-0733.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"1388_CR105","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1021\/acs.nanolett.6b01994","volume":"16","author":"D Wang","year":"2016","unstructured":"Wang D, Wang T, Liu J, et al. Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy. Nano Lett. 2016;16(9):5503\u201313. https:\/\/doi.org\/10.1021\/acs.nanolett.6b01994.","journal-title":"Nano Lett"},{"issue":"5","key":"1388_CR106","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1021\/acsnano.7b00715","volume":"11","author":"J Xu","year":"2017","unstructured":"Xu J, Xu L, Wang C, et al. Near-Infrared-Triggered Photodynamic Therapy with Multitasking Upconversion Nanoparticles in Combination with Checkpoint Blockade for Immunotherapy of Colorectal Cancer. ACS Nano. 2017;11(5):4463\u201374. https:\/\/doi.org\/10.1021\/acsnano.7b00715.","journal-title":"ACS Nano"},{"issue":"38","key":"1388_CR107","doi-asserted-by":"publisher","first-page":"12502","DOI":"10.1021\/jacs.6b06663","volume":"138","author":"K Lu","year":"2016","unstructured":"Lu K, He C, Guo N, et al. Chlorin-Based Nanoscale Metal-Organic Framework Systemically Rejects Colorectal Cancers via Synergistic Photodynamic Therapy and Checkpoint Blockade Immunotherapy. J Am Chem Soc. 2016;138(38):12502\u201310. https:\/\/doi.org\/10.1021\/jacs.6b06663.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"1388_CR108","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12951-021-00919-z","volume":"19","author":"X Yang","year":"2021","unstructured":"Yang X, Zhang W, Jiang W, et al. Nanoconjugates to enhance PDT-mediated cancer immunotherapy by targeting the indoleamine-2,3-dioxygenase pathway. J Nanobiotechnol. 2021;19(1):182. https:\/\/doi.org\/10.1186\/s12951-021-00919-z.","journal-title":"J Nanobiotechnol"},{"key":"1388_CR109","doi-asserted-by":"publisher","first-page":"102671doi","DOI":"10.1016\/j.pdpdt.2021.102671","volume":"37","author":"XY Wang","year":"2022","unstructured":"Wang XY, Maswikiti EP, Zhu JY, et al. Photodynamic therapy combined with immunotherapy for an advanced esophageal cancer with an obstruction post metal stent implantation: A case report and literature review. Photodiagn Photodyn Ther. 2022;37:102671doi. https:\/\/doi.org\/10.1016\/j.pdpdt.2021.102671.","journal-title":"Photodiagn Photodyn Ther"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01388-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01388-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01388-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:23:02Z","timestamp":1775553782000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01388-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1388"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01388-y","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All the authors consent for the publication of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}